Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Maximilian J Mair, Emeline Tabouret, Derek R Johnson, Erik P Sulman, Patrick Y Wen, Matthias Preusser, Nathalie L Albert
Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grade 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters...
May 4, 2024: Neuro-oncology
#2
JOURNAL ARTICLE
Wafa Baqri, Kathryn Rzadki, Steven Habbous, Sunit Das
BACKGROUND AND PURPOSE: Glioblastoma (GBM) is the most common malignant primary brain tumour in adults. Receipt of adjuvant therapies has been shown to exert a significant positive effect on patient survival. Little is known however about how changes in standards of care and healthcare system factors, such as access, affect real-world outcomes. In this study, we provide an overview of GBM in Ontario and examine elements of care, including treatment patterns, healthcare utilization, and overall survival, from 2010 to 2019, to interpret the impact of the changes in practice standards and expansion of the care network within this period...
May 3, 2024: Journal of Neuro-oncology
#3
JOURNAL ARTICLE
Kelsi M Chesney, Gregory F Keating, Nirali Patel, Lindsay Kilburn, Adriana Fonseca, Cheng-Chia Wu, Javad Nazarian, Roger J Packer, Daniel A Donoho, Chima Oluigbo, John S Myseros, Robert F Keating, Hasan R Syed
INTRODUCTION: Focused ultrasound (FUS) is an innovative and emerging technology for the treatment of adult and pediatric brain tumors and illustrates the intersection of various specialized fields, including neurosurgery, neuro-oncology, radiation oncology, and biomedical engineering. OBJECTIVE: The authors provide a comprehensive overview of the application and implications of FUS in treating pediatric brain tumors, with a special focus on pediatric low-grade gliomas (pLGGs) and the evolving landscape of this technology and its clinical utility...
May 3, 2024: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
#4
JOURNAL ARTICLE
Ilah Shin, Yongsik Sim, Seo Hee Choi, Yae Won Park, Narae Lee, Sung Soo Ahn, Jong Hee Chang, Se Hoon Kim, Seung-Koo Lee
PURPOSE: There is lack of comprehensive analysis evaluating the impact of clinical, molecular, imaging, and surgical data on survival of patients with gliomatosis cerebri (GC). This study aimed to investigate prognostic factors of GC in adult-type diffuse glioma patients. METHODS: Retrospective chart and imaging review was performed in 99 GC patients from adult-type diffuse glioma (among 1,211 patients; 6 oligodendroglioma, 16 IDH-mutant astrocytoma, and 77 IDH-wildtype glioblastoma) from a single institution between 2005 and 2021...
May 3, 2024: Journal of Neuro-oncology
#5
JOURNAL ARTICLE
Santosh Valvi, Neevika Manoharan, Marion K Mateos, Timothy Eg Hassall, David S Ziegler, Geoffrey B McCowage, Matthew D Dun, David D Eisenstat, Nicholas G Gottardo, Jordan R Hansford
INTRODUCTION: The main mission of the Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG) is to develop and facilitate local access to the world's leading evidence-based clinical trials for all paediatric cancers, including brain tumours, as soon as practically possible. Diffuse intrinsic pontine gliomas (DIPGs) - a subset of a larger group of tumours now termed diffuse midline glioma, H3K27-altered (DMG) - are paediatric brain cancers with less than 10% survival at two years...
May 3, 2024: Medical Journal of Australia
#6
JOURNAL ARTICLE
Anna Cecilia Lawson McLean, Aaron Lawson McLean, Thomas Ernst, Marie-Therese Forster, Christian Freyschlag, Jens Gempt, Roland Goldbrunner, Stefan Grau, Christine Jungk, Birgitt van Oorschot, Steffen K Rosahl, Ulrich Wedding, Christian Senft, Marcel A Kamp
PURPOSE: To benchmark palliative care practices in neurooncology centers across Germany, evaluating the variability in palliative care integration, timing, and involvement in tumor board discussions. This study aims to identify gaps in care and contribute to the discourse on optimal palliative care strategies. METHODS: A survey targeting both German Cancer Society-certified and non-certified university neurooncology centers was conducted to explore palliative care frameworks and practices for neurooncological patients...
May 2, 2024: Journal of Neuro-oncology
#7
JOURNAL ARTICLE
Justin Z Wang, Alexander P Landry, David R Raleigh, Felix Sahm, Kyle M Walsh, Roland Goldbrunner, Leeor S Yefet, Jörg C Tonn, Chloe Gui, Quinn T Ostrom, Jill Barnholtz-Sloan, Arie Perry, Yosef Ellenbogen, C Oliver Hanemann, Gerhard Jungwirth, Michael D Jenkinson, Ghazaleh Tabatabai, Tiit I Mathiesen, Michael W McDermott, Marcos Tatagiba, Christian la Fougère, Sybren L N Maas, Norbert Galldiks, Nathalie L Albert, Priscilla K Brastianos, Felix Ehret, Giuseppe Minniti, Katrin Lamszus, Franz L Ricklefs, Jens Schittenhelm, Katharine J Drummond, Ian F Dunn, Omar N Pathmanaban, Aaron Cohen-Gadol, Erik P Sulman, Emeline Tabouret, Emelie Le Rhun, Christian Mawrin, Jennifer Moliterno, Michael Weller, Wenya Linda Bi, Andrew Gao, Stephen Yip, Maximilian Niyazi, Kenneth Aldape, Patrick Y Wen, Susan Short, Matthias Preusser, Farshad Nassiri, Gelareh Zadeh
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and the rising availability of neuroimaging. While most exhibit non-malignant behaviour, a subset of meningiomas are biologically aggressive and lead to significant neurological morbidity and mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication...
May 2, 2024: Neuro-oncology
#8
JOURNAL ARTICLE
Josephine D Hendriksen, Alessio Locallo, Simone Maarup, Olivia Debnath, Naveed Ishaque, Benedikte Hasselbach, Jane Skjøth-Rasmussen, Christina Westmose Yde, Hans S Poulsen, Ulrik Lassen, Joachim Weischenfeldt
BACKGROUND: Glioblastoma is a highly aggressive type of brain tumour for which there is no curative treatment available. Immunotherapies have shown limited responses in unselected patients, and there is an urgent need to identify mechanisms of treatment resistance to design novel therapy strategies. METHODS: Here we investigated the phenotypic and transcriptional dynamics at single-cell resolution during nivolumab immune checkpoint treatment of glioblastoma patients...
May 2, 2024: Neuro-oncology
#9
JOURNAL ARTICLE
Ameya D Puranik, Indraja D Dev, Venkatesh Rangarajan, Suyash Kulkarni, Nitin Shetty, Kunal Gala, Arpita Sahu, Kajari Bhattacharya, Archya Dasgupta, Abhishek Chatterjee, Tejpal Gupta, Epari Sridhar, Ayushi Sahay, Prakash Shetty, Vikas Singh, Aliasgar Moiyadi, Nandini Menon, Nilendu C Purandare, Archi Agrawal, Sneha Shah, Sayak Choudhury, Suchismita Ghosh, Ashish Kumar Jha
PURPOSE: Refractory and/or recurrent meningiomas have poor outcomes, and the treatment options are limited. Peptide receptor radionuclide therapy (PRRT) has been used in this setting with promising results. We have documented our experience of using intravenous (IV) and intra-arterial (IA) approaches of Lu-177 DOTATATE PRRT. METHODS: Eight patients with relapsed/refractory high-grade meningioma received PRRT with Lu-177 DOTATATE by IV and an IA route. At least 2 cycles were administered...
March 1, 2024: Neurology India
#10
JOURNAL ARTICLE
Hajime Yonezawa, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Katsunori Asai, Noriko Fukuhara, Kazuhiko Sugiyama, Naoki Shinojima, Arata Aoi, Ryo Nishikawa
BACKGROUND: The ONO-4059-02 phase 1/2 study showed favorable efficacy and acceptable safety profile of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, for relapsed/refractory primary central nervous system lymphoma (PCNSL). Here, we report the long-term efficacy and safety after a 3-year follow-up. METHODS: Eligible patients were aged ≥ 20 years with histologically diagnosed PCNSL and KPS of ≥ 70. Patients received oral tirabrutinib once daily at 320 or 480 mg, or 480 mg under fasted conditions...
2024: Neuro-oncology advances
#11
JOURNAL ARTICLE
Gang Li, Qilong Tian, Shoujie Wang, Kailu Li, Yu Zhang, Qing Cai
INTRODUCTION: Meningiomas with bone involvement account for 4.5-17% of all intracranial meningiomas. Little is known about whether these meningiomas (WHO grade I) behave differently than meningiomas without bone involvement. We sought to study the relatively uncommon imaging manifestations of meningioma and to evaluate their clinical significance. METHODS: A single-institution retrospective cohort study of surgically treated superficial meningioma patients between 2011 and 2022 was conducted...
April 30, 2024: Journal of Neuro-oncology
#12
JOURNAL ARTICLE
Mustafa M Basree, Chengnan Li, Hyemin Um, Anthony H Bui, Manlu Liu, Azam Ahmed, Pallavi Tiwari, Alan B McMillan, Andrew M Baschnagel
OBJECTIVE: Radiation necrosis (RN) can be difficult to radiographically discern from tumor progression after stereotactic radiosurgery (SRS). The objective of this study was to investigate the utility of radiomics and machine learning (ML) to differentiate RN from recurrence in patients with brain metastases treated with SRS. METHODS: Patients with brain metastases treated with SRS who developed either RN or tumor reccurence were retrospectively identified. Image preprocessing and radiomic feature extraction were performed using ANTsPy and PyRadiomics, yielding 105 features from MRI T1-weighted post-contrast (T1c), T2, and fluid-attenuated inversion recovery (FLAIR) images...
April 30, 2024: Journal of Neuro-oncology
#13
JOURNAL ARTICLE
Divya Yadav, Rituraj Upadhyay, Vinodh A Kumar, Melissa M Chen, Jason M Johnson, Holly Langshaw, Brandon J Curl, Maguy Farhat, Wasif Talpur, Thomas H Beckham, Debra N Yeboa, Todd A Swanson, Amol J Ghia, Jing Li, Caroline Chung
BACKGROUND: A dedicated MRI Simulation(MRsim) for radiation treatment(RT) planning in high-grade glioma(HGG) patients can detect early radiological changes, including tumor progression after surgery and before standard of care chemoradiation. This study aimed to determine the impact of using post-op MRI vs. MRsim as the baseline for response assessment and reporting pseudo-progression on follow-up imaging at one month(FU1) after chemoradiation. METHODS: Histologically confirmed HGG patients were planned for six weeks of RT in a prospective study for adaptive RT planning...
April 27, 2024: Practical Radiation Oncology
#14
JOURNAL ARTICLE
Francesco Bruno, Alessia Pellerino, Marco Conti Nibali, Edoardo Pronello, Fabio Cofano, Marco Rossi, Mario Levis, Luca Bertero, Riccardo Soffietti, Paola Cassoni, Diego Garbossa, Lorenzo Bello, Roberta Rudà
BACKGROUND AND OBJECTIVES: Patients with IDH1/2 -mutant lower-grade glioma have a high frequency of seizures. We aimed to investigate the correlations between seizures and tumor/patient characteristics and the impact of surgery and adjuvant treatments (AT) on seizure control along the disease trajectory. METHODS: We retrospectively included patients with IDH1/2 -mutant lower-grade glioma who underwent surgery at the neurosurgery divisions of the University of Turin and Milan and were treated at the Division of Neuro-Oncology of Turin...
May 2024: Neurology
#15
JOURNAL ARTICLE
Janette Herr, Radka Stoyanova, Eric Albert Mellon
Deep learning (DL) is poised to redefine the way medical images are processed and analyzed. Convolutional neural networks (CNNs), a specific type of DL architecture, are exceptional for high-throughput processing, allowing for the effective extraction of relevant diagnostic patterns from large volumes of complex visual data. This technology has garnered substantial interest in the field of neuro-oncology as a promising tool to enhance medical imaging throughput and analysis. A multitude of methods harnessing MRI-based CNNs have been proposed for brain tumor segmentation, classification, and prognosis prediction...
2024: Critical Reviews in Oncogenesis
#16
JOURNAL ARTICLE
Alejandro Lastra Romero, Thea Seitz, Georgios Alkis Zisiadis, Holli Jeffery, Ahmed M Osman
BACKGROUND: Cranial radiotherapy is standard of care for high-grade brain tumors and metastases; however, it induces debilitating neurocognitive impairments in cancer survivors, especially children. As the numbers of pediatric brain cancer survivors continue improving, the numbers of individuals developing life-long neurocognitive sequalae are consequently expected to rise. Yet, there are no established biomarkers estimating the degree of the irradiation-induced brain injury at completion of radiotherapy to predict the severity of the expected neurocognitive complications...
April 29, 2024: Neuro-oncology
#17
JOURNAL ARTICLE
Barbara Castelli, Mirko Scagnet, Federico Mussa, Lorenzo Genitori, Iacopo Sardi, Stefano Stagi
BACKGROUND: Craniopharyngioma (CP), although slow growing and histologically benign, has high morbidity, mostly related to hypothalamus-pituitary dysfunction and electrolyte imbalance. Increased risk of vascular complications has been described. However, data are still poor, especially in the paediatric population. The aim of our study was to evaluate the occurrence, timing, and predisposing factors of deep venous thrombosis (DVT) and other vascular alterations in neurosurgical paediatric CP patients...
2024: Frontiers in Endocrinology
#18
JOURNAL ARTICLE
Laura Alder, Gloria Broadwater, Michelle Green, Amanda E D Van Swearingen, Eric S Lipp, Jeffrey Melson Clarke, Carey K Anders, Sarah Sammons
BACKGROUND: Although serum circulating tumor DNA (ctDNA) is routine, data from patients with brain metastases (BrMs) is limited. We assessed genomic alterations in ctDNA from patients with solid tumor BrMs in 3 groups: Isolated BrMs with stable extracranial disease (iCNS), concurrent brain and extracranial progression (cCNS), and extracranial progression with no active BrMs (eCNS). We also compared ctDNA alterations between patients with and without BrMs. METHODS: Patients with a Guardant360 ctDNA profile with ( n = 253) and without BrMs ( n = 449) from the Duke Molecular Registry between January 2014 and December 2020 were identified...
2024: Neuro-oncology advances
#19
JOURNAL ARTICLE
Prajwal Ghimire, Ben Kinnersley, Golestan Karami, Prabhu Arumugam, Richard Houlston, Keyoumars Ashkan, Marc Modat, Thomas C Booth
BACKGROUND: Immunotherapy is an effective "precision medicine" treatment for several cancers. Imaging signatures of the underlying genome (radiogenomics) in glioblastoma patients may serve as preoperative biomarkers of the tumor-host immune apparatus. Validated biomarkers would have the potential to stratify patients during immunotherapy clinical trials, and if trials are beneficial, facilitate personalized neo-adjuvant treatment. The increased use of whole genome sequencing data, and the advances in bioinformatics and machine learning make such developments plausible...
2024: Neuro-oncology advances
#20
JOURNAL ARTICLE
Tiffany M Juarez, Jaya M Gill, Annie Heng, Jose A Carrillo, Naveed Wagle, Natsuko Nomura, Minhdan Nguyen, Judy Truong, Lucia Dobrawa, Walavan Sivakumar, Garni Barkhoudarian, Daniel F Kelly, Santosh Kesari
BACKGROUND: Afatinib (BIBW2992; Gilotrif®) is a selective and irreversible inhibitor of the epidermal growth factor receptor (ErbB; EGFR) family. It inhibits EGFR, HER2, and HER4 phosphorylation, resulting in tumor growth inhibition and regression. This phase I dose-escalation trial of pulsatile afatinib examined the safety, drug penetration into the central nervous system, preliminary antitumor activity, and recommended phase II dose in patients with progressive or recurrent brain cancers...
2024: Neuro-oncology advances
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
